Evidence map›Paper›PMID 24487363›Full record

ArticleKidney international2014

The importance of quantifying genetic heterogeneity in ADPKD.

Arlene B Chapman

Open access · bronzeAbstract readComment
In one paragraph

Article in Kidney international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Arlene B ChapmanEmory University School of Medicine, Atlanta, Georgia, USA.
Emory University · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
The Early Collaborative Clinical Studies in PKD: The C*U01DK056956 · NIDDK · UNIVERSITY OF CHICAGO · PI CHAPMAN, ARLENE B · 2000 to 2016
$6.0M
Polycystic Kidney Disease Clinical Trials NetworkU01DK062408 · NIDDK · EMORY UNIVERSITY · PI RAHBARI-OSKOUI, FREDERIC FARID · 2002 to 2013
$5.7M
NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NIDDK NIH HHS U01 DK056956NIDDK NIH HHS U01 DK062408
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease. New data from Paul et al. suggest that mutations in the PKD1 and PKD2 genes may account for all cases of ADPKD. Further improvements in mutation detection methodologies are needed to determine the true relative frequency of PKD1 versus PKD2 as well as to establish the value of mutation type and location to predict disease severity in this disorder.

Indexed as

Genetic LociMutationFemaleHumansMalePolycystic Kidney, Autosomal DominantTRPP Cation ChannelsTRPP Cation Channels

Identifiers

PMID24487363
PMCPMC3914150
OpenAlexW2084448977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.